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Abstract
Background: Prospective studies have indicated that elevated blood glucose levels may be linked with increased cancer
risk, but the strength of the association is unclear. We examined the association between blood glucose and cancer risk in a
prospective study of six European cohorts.
Methods and Findings: The Metabolic syndrome and Cancer project (Me-Can) includes cohorts from Norway, Austria, and
Sweden; the current study included 274,126 men and 275,818 women. Mean age at baseline was 44.8 years and mean
follow-up time was 10.4 years. Excluding the first year of follow-up, 18,621 men and 11,664 women were diagnosed with
cancer, and 6,973 men and 3,088 women died of cancer. We used Cox regression models to calculate relative risk (RR) for
glucose levels, and included adjustment for body mass index (BMI) and smoking status in the analyses. RRs were corrected
for regression dilution ratio of glucose. RR (95% confidence interval) per 1 mmol/l increment of glucose for overall incident
cancer was 1.05 (1.01–1.10) in men and 1.11 (1.05–1.16) in women, and corresponding RRs for fatal cancer were 1.15 (1.07–
1.22) and 1.21 (1.11–1.33), respectively. Significant increases in risk among men were found for incident and fatal cancer of
the liver, gallbladder, and respiratory tract, for incident thyroid cancer and multiple myeloma, and for fatal rectal cancer. In
women, significant associations were found for incident and fatal cancer of the pancreas, for incident urinary bladder
cancer, and for fatal cancer of the uterine corpus, cervix uteri, and stomach.
Conclusions: Data from our study indicate that abnormal glucose metabolism, independent of BMI, is associated with an
increased risk of cancer overall and at several cancer sites. Our data showed stronger associations among women than
among men, and for fatal cancer compared to incident cancer.
Please see later in the article for the Editors’ Summary.
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Elevated blood glucose has been associated with an increased
risk of cancer overall in several prospective studies [1–6]. The
strongest evidence comes from a Korean cohort study of 1.3
million men and women that reported an increased risk of incident
as well as of fatal cancer in individuals with high glucose levels [1].
Prospective studies of glucose and cancer risk in cohorts of
European and US populations have been much smaller, and these
studies did not concurrently report on risk of incident and fatal
cancer [2–7]. Previous results from cohorts in Austria [2] and
Sweden [3] included in the current study, also indicated that
elevated fasting glucose is related to an increased risk of overall
incident cancer. However, the relatively modest sample size in
these studies resulted in limited power to estimate risks for
individual cancer sites. Furthermore, exposure assessment by
glucose measurement at a single occasion entails a substantial
random error owing to technical measurement error and within-
person variation of blood glucose level [8,9]. Such inaccuracy of
exposure assessment will dilute the association with outcome, i.e.,
regression dilution bias [8,10,11]. In several prospective studies of
metabolic factors and risk of cardiovascular disease, data from
multiple examinations have been used to correct risk estimates for
random error in exposure classification, which resulted in
substantially stronger associations than estimates on the basis of
uncorrected exposures [12–14]. To date, correction for random
error has only been performed in one study on glucose and cancer
risk [3].
The aim of this study was to investigate the association between
blood glucose and risk of incident and fatal cancer overall and at
specific sites, as well as all-cause mortality, in a large study of six
European cohorts including correction for random error in
glucose levels.
Material and Methods
Me-Can
The Metabolic syndrome and Cancer project (Me-Can)
includes data from population-based cohorts in Norway, Austria,
and Sweden. A detailed description of Me-Can has recently been
published [15]. In brief, the Norwegian cohorts includes the Oslo
study I cohort (Oslo) [16,17], the Norwegian Counties Study
(NCS) [18,19], the Cohort of Norway (CONOR) [20], and
the Age 40-programme (40-y) [21]. The Austrian cohort consists
of the Vorarlberg Health Monitoring and Prevention Programme
(VHM&PP) [2], and the Swedish cohorts are the Va ¨sterbotten
Intervention Project (VIP) [22], and the Malmo ¨ Preventive
Project (MPP) [23,24]. Written informed consent was obtained
from all participants included in this study, and the study was
approved by research ethical committees in the respective
countries.
Data on height, weight, blood pressure, and blood, plasma, or
serum levels of glucose, total cholesterol, and triglycerides had
been collected at health examinations in all cohorts. Height and
weight were measured in a similar way in all cohorts; without
shoes and with light indoor clothing. In the Norwegian cohorts,
fasting was not required before the examination, and fasting time
was recorded as ,1 h, 1–2, 2–4, 4–8, or .8 h. Fasting time in the
VIP was recorded as ,4 h, 4–8, or .8 h, and from 1992,
participants were asked to fast for at least 8 h before the
examination. In the MPP and after the initial 3 y in the
VHM&PP, a minimum of 8 h fasting time before blood draw
was implemented. Glucose levels were measured in the Oslo and
the NCS in serum glucose with a nonenzymatic method; in
CONOR and the 40-y cohort, serum/enzymatic; in the
VHM&PP and the VIP, plasma/enzymatic; and in the MPP,
whole blood/enzymatic. In the Norwegian cohorts, the nonenzy-
matic method used during the first study period yielded 0.8–
1.1 mmol/l higher levels than by the use of an enzymatic method
[25]. Data from several health examinations were available for a
subset of individuals in some of the Me-Can cohorts [15], and for
each person in the study, data from one health examination
constituted the baseline observation, described as follows.
Follow-up and Selection of Participants
Each of the cohorts was linked to the respective national
registers for identification of (a) cancer diagnosis, (b) migration, (c)
vital status, and (d) cause of death, with death attributed to cancer
if the underlying cause of death was cancer. Follow-up for each of
the cohorts includes the year as follows: Norwegian cohorts, (a–c)
2005, (d) 2004; the VHM&PP, (a) 2003, (b) no information
available, (c, d) 2003; the VIP and the MPP (a–c) 2006, (d) 2004.
Selection of individuals for the study is described in Figure 1.
From the original data with 904,060 individuals and 1,600,296
observations, we excluded observations with: nonmatching data, a
cancer diagnosis at or before the date of health examination,
extreme values of metabolic factors [15] (,1 mmol/l for glucose
and ,15 or .60 kg/m
2 for body mass index [BMI]), missing data
for BMI, glucose or fasting time, a shorter time than 1 y between
the date of examination and end of follow-up for cancer incidence,
and observations in the VHM&PP that included data on postload
glucose instead of fasting glucose. Out of the 574,356 excluded
observations, 414,629 observations were excluded in the Norwe-
gian cohorts in individuals for whom data on glucose were missing,
as blood glucose had not been measured as a standard in these
cohorts throughout all time-periods. From the remaining 611,459
individuals with 1,025,940 observations, we selected the first
observation for each individual, and if data from a fasting state and
data on smoking status were available, the first of these
observations was selected. Thus, for each individual, data were
included from the first health examination with complete data to
comprise the baseline set of measurements. Due to policy
restrictions imposed by the Norwegian Institute of Public Health
that the proportion of Norwegian individuals in Me-Can studies
should not exceed approximately 50% (56% after the above
selection), we further excluded 1,868 individuals in Norway
without data on smoking status, and the entire NCS cohort
(n=59,647). The reason for excluding an entire cohort was to keep
the included Norwegian cohorts intact and to keep down the
number of strata in statistical analyses, as a large number of strata
reduce statistical power. We excluded the NCS cohort as it
consisted of approximately the number of individuals that was
required to be excluded. The final dataset included 549,944
individuals, 274,126 men and 275,818 women.
Categorisation of Cancers
Incident and fatal cancers, categorised according to the
International Classification of Diseases, seventh revision (ICD-7)
codes, were grouped into cancer sites as grouped in the Eurostat
European shortlist for cause of death [26], which was used for
cause of death classification in the Norwegian cohorts. Incident
cancers were further divided into relevant subgroups. Relative
risks (RR) for incident and fatal cancer at specific sites are
presented separately for men and women if the number of cases in
each group was .50, and risks are presented for men and women
combined if the number of cases in each group was #50 and if the
total number of cases was .80.
Glucose and Cancer Risk
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In order to reduce the probability of reverse causation, rates,
RRs and absolute risks were calculated with follow-up starting 1 y
after the baseline examination. Individuals were followed until the
date of event, i.e., cancer diagnosis or cancer death, or until the
date of death from any cause, emigration, or end of follow-up,
whichever occurred first. Rates were directly age-standardized in
5-y categories, using the European standard population as the
reference [27]. We used Cox proportional hazards regression to
calculate hazard ratios, denoted as RRs, for glucose levels with risk
of incident and fatal cancer, and of death from all causes. Age was
used as time variable and all estimates were stratified by subcohort,
sex, and by categories of birth date: before 1923, 1923–1930,
1931–1938, 1939–1946, 1947–1954, 1955, and later. We
estimated RR for glucose levels in quintiles and deciles, for which
cut-off levels were calculated within each subcohort, sex, and
category of fasting time. p for trend over quintiles and deciles refers
to the p-value for the Wald test of a linear risk estimate, assigning
participants included in each analysis the mean sex- and cohort-
specific glucose level within the corresponding quantile. RR was
also assessed for glucose as a continuous variable, i.e., per
1 mmol/l increment. In order to exclude outliers, these analyses
were restricted to individuals with glucose levels lower than
10 mmol/l (99% of individuals). All analyses included adjustment
for age at measurement (continuous), BMI (categories: ,22.5, 22.5
to ,25.0, 25.0 to ,27.5, 27.5 to ,30.0, 30.0 to ,32.5 kg/m
2)
and smoking status (categories: never smoker, ex-smoker, current
smoker, and unknown), and analyses of glucose as a continuous
variable were also adjusted for fasting time.
We calculated regression dilution ratio (RDR) of glucose in
order to adjust RRs for random error in glucose level [8,10,11].
RDR was calculated on the basis of data from repeated health
examinations in 133,820 individuals, including 406,364 observa-
tions, in the full Me-Can cohort. Only repeated measurements
with the same fasting time and in the same cohort as at baseline,
and with data on smoking status, were used. However, as the same
method for glucose measurement had been used in the Oslo and
the NCS cohorts, and in the CONOR and 40-y cohorts,
participants with measurements in the Oslo and in the NCS, or
in CONOR and in the 40-y cohort, were included in analyses.
Mean time between the baseline measurement and repeated
measurements was 6.9 y (standard deviation [SD]=3.9). We used
a linear mixed effects model, similar to that described by Wood et
al. [11], which included age at baseline, fasting time, smoking
status, sex, and time from baseline as fixed effects, and cohort as
random effect. RDR was estimated separately for men and
women, and combined, in models for (a) glucose standardised
within cohort, sex and fasting time, and for (b) glucose only
including individuals with a baseline glucose level lower than
10 mmol/l. Model (a) was used to predict RDR among individuals
in the current study with data on smoking status, for correction of
RRs in quantiles, and model (b) was used to predict RDR among
individuals with data on smoking status and with a glucose level
lower than 10 mmol/l, for correction of RRs of per 1 mmol/l
increment. RDR was predicted for the time point at 5 y after
baseline measurement, i.e., half the follow-up time [8,10,11]. We
used the mean of predicted RDRs for correction of RR, which
resulted in RDRs for quantile analyses of: 0.30 among men, 0.30
among women, and 0.31 overall, and in analyses of per 1 mmol/l
increment: 0.40 among men, 0.43 among women, and 0.41
overall. Correction of RRs for RDR was obtained by exp
(log(RR)/RDR), using the sex-specific RDR in analyses that
included men or women only, and using the combined RDR in
analyses that included both sexes.
Cox proportional hazards assumption was checked for glucose
and covariates by the statistical test of Schoenfeld residuals. For
some cancers, there was an indication of violation of proportion-
ality for BMI or smoking status, but as RRs were very similar with
and without stratification of the variable within the model, BMI
and smoking status were not kept as stratum in the final model.
For a few cancers there was an indication of violation of the
proportionality over age for glucose; however, we report RRs only
in the full study group and not in subgroups of age. Interaction
between glucose and (a) BMI, (b) fasting time, and (c) cohort on the
risk of overall incident and fatal cancer was checked by analysing
RRs in subgroups of BMI, fasting time, and cohort, and by
performing likelihood ratio tests comparing the model used to
assess RR per 1 mmol/l increment with a model that additionally
included a product term of continuous glucose and categories of
BMI, fasting time, or cohort, respectively. Interaction between
glucose and fasting time was assessed in the Norwegian cohorts.
Evidence of a nonlinear association between glucose and risk of
overall incident and fatal cancer was tested by likelihood ratio test,
comparing the model with glucose as a continuous variable with a
model that also included an x
2 term of glucose. In order to assess
linearity across the whole glucose range, all individuals were
included in this analysis. Absolute risks of incident and fatal cancer
between 50 and 70 y of age were calculated as described by Gail et
al. [28]. For this method, risk of cancer and of dying from other
causes than cancer was derived from the cohort for ages 50 to 60 y
and 60 to 70 y, respectively. Statistical analyses were performed in
Stata (version 9.2, StataCorp LP), and R (version 2.7.2, used for
RDR calculation).
Results
Baseline Characteristics and Follow-up
Mean age at baseline was 44.7 y (SD=11.6) in men and 45.0 y
(SD=12.8) in women (Table 1). The prevalence of overweight or
obesity, i.e., BMI 25 kg/m
2 or higher, was 56% among men and
42% among women. All participants in the VHM&PP and the
MPP and 90% of participants in the VIP had fasted .8 h before
the health examination, whereas 95% of participants in the
Norwegian cohorts had fasted ,8 h. Among individuals that had
fasted .8 h, 8% of men and 6% of women had impaired glucose
levels according to the World Health Organization definition [29]
(6.1–6.9 mmol/l in serum/plasma or 5.6–6.0 mmol/l in whole
blood), and 4% of men and 3% of women had diabetic glucose
levels ($7.0 mmol/l in serum/plasma or $6.1 mmol/l in whole
blood). Baseline age and BMI increased for each increment of
glucose quintile (Table 2).
The mean follow-up time was 11.3 y (SD=7.4) in men and
9.6 y (SD=4.4) in women. Excluding the first year of observation,
18,621 men and 11,664 women were diagnosed with cancer
during follow-up and 6,973 men and 3,088 women died of cancer.
Glucose and RR of Cancer
Glucose was significantly positively associated with risk of
overall incident and fatal cancer. In men, the RR (95% confidence
interval [CI]) per 1 mmol/l increment was for incident cancer
Figure 1. Flowchart of data cleaning and selection of individuals/observations. OGTT, oral glucose tolerance test. NCS, Norwegian
Counties Study.
doi:10.1371/journal.pmed.1000201.g001
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and 4). In analysis of glucose in quintiles, the RR for the top versus
bottom quintile was for incident cancer 1.18 (1.00–1.37, p for
trend=0.06), and for fatal cancer 1.50 (1.18–1.94, p for
trend,0.001). Significant increases in risk of incident and fatal
cancer at specific sites per 1 mmol/l increment in glucose among
men were observed for cancer of the liver, gallbladder, and the
respiratory tract. Significant linear associations were also found for
incident thyroid cancer, multiple myeloma, and for fatal rectal
cancer, and glucose in the top quintile was associated with a
significant increased risk of fatal colon cancer.
In women, the association between a 1 mmol/l increase in
glucose level and overall cancer was somewhat stronger than
in men; the RR among women for incident cancer was 1.11
(1.05–1.16), and for fatal cancer 1.21 (1.11–1.33) (Tables 3 and 4).
Significant positive associations among women were observed for
incident and fatal cancer of the pancreas, and stomach (borderline
significant for incidence). A significant linear association was also
observed for incident urinary bladder cancer and for fatal cervix
and uterine corpus cancer. Furthermore, top quintile level of
glucose was significantly associated with an increased risk of
incident endometrial cancer, and a decreased risk of incident
thyroid cancer.
In men and women combined, a 1 mmol/l increment in glucose
level was associated with an increased risk of death from cancer of
the oropharynx and oesophagus.
BMI and fasting time before blood draw had no effect on the
association between glucose and risk of cancer overall in men or in
women (p for interaction, all .0.05). There was no significant
interaction between glucose and subcohort on the risk of incident
and fatal cancer in men, or for fatal cancer in women (p for
interaction, all .0.05). However, the association between glucose
and risk of incident cancer in women differed significantly between
the cohorts; the overall p-value for interaction was 0.02, and the
RR per 1 mmol/l increment of glucose ranged between 0.98
(0.84–1.12) in the 40-y cohort, and 1.30 (1.15–1.50) in the VIP. No
similar pattern was observed in men, among whom the RR for
incident cancer was lowest in the VIP (RR=0.95) and highest in
the VHM&PP.
Decile Levels of Glucose and Risk
We further explored risk of cancer by decile categories of
glucose levels. In order to use a broad referent category that
includes healthy normal glucose levels, we used the lowest 40% of
glucose levels as referent group. Among fasting individuals, the
cut-off for impaired fasting glucose was in the top 10%–20% of
glucose levels. The association between glucose level and cancer
risk was approximately linear across the full range of glucose levels
(Figures 2 and 3), and the extension of a linear model with an x
2
variable did not significantly improve the fit of the association with
incident or fatal cancer among men or women (p, all .0.05). In
men, the RR for top decile versus decile 1–4 for incident cancer
was 1.14 (0.97–1.33, p for trend=0.09), and for fatal cancer 1.84
(1.46–2.40, p for trend,0.001). RRs of total cancer, excluding
prostate cancer, were for incident cancer 1.37 (1.14–1.64, p for
trend=0.002), and for fatal cancer 2.10 (1.59–2.72, p for
trend,0.001). In women, the RR for top decile versus decile
1–4 for overall incident cancer was 1.42 (1.18–1.74, p for
trend,0.001), and for fatal cancer 2.05 (1.42–2.93, p for
trend,0.001). The corresponding RR for overall death was in
Table 2. Characteristics of individuals within quintile levels of glucose.
Characteristics Sex Quintile 1–5
12345
Glucose, mmol/l, mean (SD) Men 4.1 (0.5) 4.7 (0.3) 5.1 (0.3) 5.5 (0.4) 6.9 (2.0)
Women 4.0 (0.5) 4.6 (0.3) 4.9 (0.3) 5.3 (0.3) 6.5 (1.7)
Baseline age, y, mean (SD) Men 42.5 (11.1) 43.3 (11.1) 44.1 (11.4) 45.1 (11.6) 48.1 (12.1)
Women 41.9 (11.7) 43.0 (11.9) 44.3 (12.5) 45.7 (12.8) 49.5 (13.5)
BMI, kg/m
2, mean (SD) Men 25.2 (3.3) 25.5 (3.3) 25.7 (3.4) 26.0 (3.5) 26.7 (3.9)
Women 24.0 (3.9) 24.5 (4.1) 24.8 (4.2) 25.2 (4.4) 26.4 (5.1)
Current smoker, % Men 29 29 28 29 29
Women 24 24 23 23 22
doi:10.1371/journal.pmed.1000201.t002
Table 1. Baseline characteristics of study individuals in Me-
Can.
Characteristics Men Women
Baseline measurement, year 1972–2005 1977–2005
Individuals, n 274,126 275,818
B a s e l i n ea g e ,y ,m e a n( S D ) 44.7 (11.6) 45.0 (12.8)
Categories, n (%) ,30 24,756 (9) 30,461 (11)
30 to ,45 143,291 (52) 141,638 (51)
45 to ,60 73,567 (27) 65,793 (24)
$60 32,512 (12) 37,926 (14)
Smoking status, n (%) Never smoker 110,154 (40) 137,767 (50)
Ex-smoker 85,094 (31) 73,263 (27)
Current smoker 77,995 (29) 64,097 (23)
Missing 883 (0) 691 (0)
BMI, kg/m
2, mean (SD) 25.8 (3.5) 25.0 (4.5)
Categories, n (%) ,25 120,026 (44) 159,700 (58)
25 to ,30 123,132 (45) 80,836 (29)
$30 30,968 (11) 35,282 (13)
F o l l o w - u p ,y ,m e a n( S D ) 11.3 (7.4) 9.6 (4.4)
Categories, n (%) ,5 39,411 (14) 39,017 (14)
5t o,15 184,479 (67) 206,769 (75)
15 to ,25 21,583 (8) 27,687 (10)
$25 28,653 (11) 2,345 (1)
doi:10.1371/journal.pmed.1000201.t001
Glucose and Cancer Risk
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PLoS Medicine | www.plosmedicine.org 9 December 2009 | Volume 6 | Issue 12 | e1000201Figure 2. RR (95% CI) in men of incident (n=18,621) and fatal (n=6,973) cancer by deciles of glucose. The risk estimates for decile
categories are plotted on the x-axis at the mean glucose level for each decile category. IFG indicates the range of impaired fasting glucose in the
cohorts among individuals that had fasted more than 8 h before the blood draw, and DM indicates the range of diabetic glucose levels. Glucose
levels in the Oslo study I were recalculated (level 20.95) to correspond with enzymatic levels.
doi:10.1371/journal.pmed.1000201.g002
Figure 3. RR (95% CI) in women of incident (n=11,664) and fatal (n=3,088) cancer by deciles of glucose. The risk estimates for decile
categories are plotted on the x-axis at the mean glucose level for each decile category. IFG indicates the range of impaired fasting glucose in the
cohorts among individuals that had fasted more than 8 h before the blood draw, and DM indicates the range of diabetic glucose levels.
doi:10.1371/journal.pmed.1000201.g003
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(3.00–4.59, p for trend,0.001).
The absolute risk of incident cancer over a 20-y period for a 50-
y old man in decile 1–4 and decile 10 of glucose was 14.0% and
15.7%, respectively, and the corresponding risk of fatal cancer was
5.0% and 8.8%. In women, the corresponding absolute risks of
developing cancer were 12.2% and 16.7%, and for cancer death,
3.0% and 6.0%, respectively.
Discussion
In this large prospective cohort study, elevated blood glucose was
significantly associated with an increased risk of incident and fatal
cancer at all sites combined, and of several specific cancers. In
women, a linear association between glucose and risk of overall
incident and fatal cancer was observed, and levels within the upper
normal range were also related to increases in risk. In men, the
associationbetweenglucose and totalincidentcancerwassomewhat
weaker, and risk of fatal cancer was only significantly increased at
levels approximately equivalent to impaired glucose levels. Women
in the top glucose decile had twice the risk of fatal cancer compared
to women with glucose levels below the 40th percentile and the risk
increase among men in the top decile was almost the same. Risk
estimateswere obtained after correction for randomerror inglucose
levels, which was high in our study in accordance with previous
observations [3,8,9]. The estimates of excess risk of fatal cancer in
the top decile corrected for regression dilution were 4-fold higher
than the uncorrected estimates. These data indicate that in previous
analyses without such correction, risk estimates for increasing
glucose may have been underestimated [1–7].
Results from our study and those from the largest study reported
to date, on men and women in Korea [1], were largely congruent
and together these studies provide strong evidence that high blood
glucose is a risk factor for cancer. In our study, associations
between glucose and overall incident and fatal cancer were
stronger in women than in men, whereas in the Korean study,
stronger associations were reported for men, for whom a
significant increased risk of fatal cancer was observed already at
levels below impaired fasting glucose. These differences between
studies may be explained by different proportions of specific
cancers in the populations. For example, prostate cancer is much
more common in Europe than in Asia [30], and as glucose was not
related to prostate cancer in either study, exclusion of prostate
cancer in analyses of total cancer in our study strengthened the
association with cancer. Type 2 diabetes has consistently been
related to an increased risk of cancer at many sites [1,31–33], and
the findings in our and the Korean study suggest also that
impaired fasting glucose levels, and to a lesser extent, also glucose
levels within the upper normal range are associated with an
increased risk of cancer.
Specific cancers for which there were strong associations
between glucose and risk of incident and fatal cancer in the
Korean study [1] and in our study, were pancreatic cancer,
particularly in women, and liver cancer in men. Moreover, both
studies showed strong associations between elevated glucose and
risk of fatal cancer of the oesophagus and cervix uteri, and of fatal
colorectal cancer in men. In our study, elevated glucose was also
associated with an increased risk of cancer of the respiratory tract
in men, and of gastric cancer in women, whereas no such
associations were found in the Korean study. Smoking is strongly
related to lung cancer and gastric cancer [34], and confounding or
interaction between glucose and smoking may possibly explain the
divergent findings. The proportion of current smokers in men was
29% in our study and 59% in the Korean study, and
corresponding proportions were 23% and 4% in women. We
observed no confounding or effect modification by smoking status
in analyses of these cancers, but residual confounding may be
present owing to an imprecise or incorrect categorisation of
smoking status.
Our study is the first to report data on glucose and risk of
oropharyngeal cancer, and suggests an increased risk of death
from these cancers in individuals with elevated glucose. Further-
more, data on prediagnostic glucose levels and risk of multiple
myeloma and thyroid cancer have previously been reported only
from the VHM&PP cohort [2]. We found a significant increase in
risk of these cancers in men with high glucose, whereas
intriguingly, risk of thyroid cancer was markedly decreased in
women with high glucose. Incidence rates of thyroid cancer are 2–
3 times higher in women than in men, possibly influenced by
female sex hormones [35–37], and we speculate that an
interaction between sex hormones and glucose may underlie our
findings, alternatively the results may be a chance finding.
Insulin and bioavailable insulin-like growth factor-I (IGF-I) are
possible links between glucose and cancer; hyperglycaemia induces
elevation of these hormones that stimulate tumour growth [38].
Glucose may also have a direct tumour-promoting effect as glucose
is used as an energy substrate in tumour cells, particularly in fast-
growing, highly proliferative tumour cells [39–41]. However, the
importance of extracellular glucose concentration for tumour
growth—and thereby a direct link between glucose itself and
cancer risk—is unclear.
Although the link between glucose and cancer may be causal,
confounding may also be involved. We controlled for two major
putative confounders, BMI and smoking, and found that the
association between glucose and cancer risk remained after
adjustment for these factors. However, other putative confounding
factors may be relevant. For example, a genetic variant with
opposite effects on risk of type 2 diabetes and prostate cancer has
recently been reported [42], and this could partly explain the null
association between glucose and prostate cancer in our study as
well as the consistently reported reduced risk of prostate cancer in
men with type 2 diabetes [43]. Various lifestyle factors, related to
glucose but with other pathways to cancer, are also potential
confounders, e.g., alcohol for cancer of the oropharynx,
oesophagus, liver, and colorectum, salt for gastric cancer, and
physical activity and fruit and vegetable consumption for a
number of cancers [44].
The association between glucose and cancer risk was stronger
for fatal cancer overall and at several sites than for incident cancer.
The explanation for this difference may vary between cancer
types. Possibly, high glucose and related factors are more
important for tumour progression than for tumour initiation.
Alternatively, persons with high glucose may be diagnosed with
cancer at a later stage, e.g., because of different health care seeking
behaviour, or the results may be caused by inconsistencies in
classification of cancer diagnosis versus cause of death [45,46].
Previous studies have consistently shown an association between
elevated glucose levels and risk of cardiovascular disease and also
to all cause mortality [1,47–49]. Accordingly, we found that
elevated glucose was strongly related to an increased risk of all
cause mortality; glucose levels in the top decile were related to a
more than 3-fold increased risk. Our data indicate that glucose
control by a healthy diet and physical activity may decrease risk of
cancer at many sites in addition to a decreased risk of
cardiovascular disease.
Strengths of our study include the large sample size from six
European population-based cohorts with virtually complete
capture of cancer cases [2,50,51], the use of incident as well as
Glucose and Cancer Risk
PLoS Medicine | www.plosmedicine.org 11 December 2009 | Volume 6 | Issue 12 | e1000201fatal cancer as endpoints, and the correction of risk estimates for
intra-individual variation of glucose levels based on a large
number of repeated measurements. In all cohorts, data were
available for BMI and smoking status, and these factors were used
as adjustment in analyses. Limitations of our study include the lack
of data on other covariates that may have influenced risk
estimates, and the different protocols for measurement of glucose
applied in subcohorts, which invalidated the use of absolute
glucose levels to our data.
In conclusion, abnormal glucose metabolism, independent of
BMI, is associated with increases in risk of cancer and cancer
death overall and at many specific sites. Furthermore, our data
showed a linear and somewhat stronger association among women
than among men, and the association was stronger for fatal
compared to incident cancer.
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Background. Large prospective population-based research
studies can have the power to discover new associations,
and to verify previously proposed associations, between
specific risk factors and the subsequent occurrence of
disease. One such study, the ‘‘Me-Can’’ (Metabolic
syndrome and Cancer project) is investigating associations
between cancer incidence and a cluster of metabolic risk
factors that make up metabolic syndrome: a large waistline; a
high level of fats called triglycerides in the blood; a low level
of ‘‘good’’ cholesterol; high blood pressure; and raised blood
glucose (hyperglycemia). Here the researchers investigate
the associations between one of these risk factors—raised
blood glucose—and cancer. It is normal for blood glucose
levels to vary before and after meals, but raised levels that
persist long-term are known to lead to organ damage and
severe complications. It is thought that more than 30% of
cancer-related deaths could be prevented by modifying key
risk factors, such as tobacco control, modifying diet, staying
active, and limiting exposure to environmental risk factors.
Why Was This Study Done? A previous large research
study (including roughly 1.3 million men and women,
conducted in Korea) has already evaluated the association
between high blood glucose levels and cancer risk, and
found that high blood glucose levels were linked with
increased risk of cancer—both getting it and dying from it.
Studies in European and US populations have also found a
link, but they considered relatively small numbers of people
and so these could not be used to calculate the risk with
respect to specific cancer sites. The researchers carrying out
the Me-Can project wanted to verify whether the
associations reported in the Korean study also held true for
European populations.
What Did the Researchers Do and Find? The researchers
identified 274,126 men and 275,818 women from existing
health studies in Norway, Austria, and Sweden for whom
data had been recorded on blood glucose level, height, and
weight. For each participant a baseline measurement was
defined, consisting of data from the first health examination,
which had complete data (including a blood glucose
measurement and whether the participant smoked). The
participants were tracked via national registers for up to
around 25 years after the baseline measurement but most
commonly for around a decade. Any cancer diagnosis was
recorded, whether the participant survived to the end of the
study, and causes of death for participants who died during
the study. The researchers analyzed the data to assess
whether a higher blood glucose level was associated with
increased risk of certain cancers, in both men and women.
The researchers took weight for height, and smoking into
account and adjusted for measurement error from additional
blood glucose measurements. The researchers found that,
overall, the higher the level of blood glucose, the higher the
risk of getting and dying from cancer. Average normal blood
glucose levels are about 5 mmol/l, also expressed as 5 mM
or 90 mg/dl. For each additional 1 mmol/l increase in blood
glucose level, the risk of getting cancer was increased by 5%
for men and 11% for women.
What Do These Findings Mean? The authors concluded
that high blood glucose is associated with increased cancer
risk. The results largely confirm findings from the Korean
study, although there are some differences in the risks of
cancers at some specific sites, which may be due to
differences in the populations such as genetics, diet, and
rates of smoking. Among the strengths of the study are its
large sample size and that glucose were measured more
than once for many individuals in the study. However, the
study is limited in that the researchers did not have data on
other possible factors such as genetics, physical activity, or
dietary factors, which are linked to cancer incidence and also
may be related to blood glucose levels. The researchers
propose that controlling blood glucose may lower cancer
risk in the population. Although this interpretation is
consistent with the data, the study design cannot
conclusively demonstrate a causal association between
glucose levels and cancer risk.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000201.
N The US National Cancer Institute provides online informa-
tion and statistics on cancer, including risk factors for
cancer
N The American Heart Association provides information on
sugars in the diet, including helpful hints on how to reduce
the amount eaten
N The UK’s National Health Service’s Change4Life campaign
provides information and ideas for those wishing to make
their lifestyle, including diet, more healthy
N Cancer Research UK is the world’s leading charity
dedicated to beating cancer through research. Its websites
provide information about cancer and the research it funds
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